Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GENinCode UK Ltd. ( (GB:GENI) ) just unveiled an update.
GENinCode Plc, a UK-based predictive genetics firm focused on cardiovascular disease and ovarian cancer, develops CE-marked molecular diagnostic tests that combine clinical algorithms and bioinformatics to assess patient risk. The company serves markets in the UK, Europe, and the U.S., aiming to advance preventative care and treatment planning through its genetic risk technologies.
The company will publish its audited final results for the year ended 31 December 2025 on 8 June 2026, followed by dedicated briefings for analysts and investors. Management will host an analyst call that morning and a live investor presentation on 10 June via the Investor Meet Company platform, underscoring efforts to engage the market and update stakeholders on performance and strategy.
Spark’s Take on GENI Stock
According to Spark, TipRanks’ AI Analyst, GENI is a Underperform.
The score is primarily weighed down by weak financial performance (persistent losses, negative operating cash flow, and declining equity). Technicals reinforce the risk with a clear downtrend and negative MACD, while valuation provides limited support due to a negative P/E and no dividend data.
To see Spark’s full report on GENI stock, click here.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based predictive genetics company specialising in genetic risk assessment for cardiovascular disease and ovarian cancer. The company operates business units in the UK, Europe via GENinCode S.L.U, and the U.S. through GENinCode U.S. Inc., offering CE-marked in vitro diagnostic molecular tests that integrate clinical algorithms and bioinformatics to support preventative care strategies.
Average Trading Volume: 6,071,691
Technical Sentiment Signal: Sell
Current Market Cap: £7.91M
For an in-depth examination of GENI stock, go to TipRanks’ Overview page.